Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

41.03 +0.69 (+1.71%)
Streaming Delayed Price Updated: 11:11 AM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67... 
Via Benzinga
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
Swing Trading Stock Watchlist For April 11 And Beyond
The stock market's health is neutral. It is not bad, but it is not great either. I’m willing to take long trades in the stocks discussed if they form valid trade setups and trigger, but I’m not being... 
Via Talk Markets
Swing Trading Stock Watchlist For April 4 And Beyond
The stock market's health has improved. That means I have the green light to buy stocks that are forming quality trade setups. Let's dive into what I have been looking at this week. 
Via Talk Markets
Xenon Pharmaceuticals's Return On Capital Employed Overview
Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in... 
Via Benzinga
Recap: Xenon Pharmaceuticals Q4 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Xenon Pharmaceuticals's Earnings: A Preview
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.... 
Via Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory... 
Via Benzinga
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi... 
Via Benzinga
Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile'
More than half of high-dose patients reported a 50% decline in monthly seizures. 
Via Investor's Business Daily
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal... 
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
Exposures COVID-19 Product Safety
Xenon Pharmaceuticals Has a Great Story But Too High a Price
XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
Xenon: Heading Toward Phase III With Strong Momentum
XENE stock is on solid footing after strong trial results 
Via InvestorPlace
New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again
XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again. 
Via InvestorPlace
Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High
Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80. Approximately 5.5 million shares have changed hands today, as compared to an... 
Via Benzinga
3 Growth Stocks Near 52-Week Highs to Buy Anyway
These top performers have what it takes to keep providing outsized gains for patient investors. 
Via The Motley Fool
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
Xenon Pharmaceuticals Raises $300M Via Equity
Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.